Genetik des Prostatakarzinoms

Bray F, Kiemeney LA (2017) Epidemiology of prostate cancer in europe: patterns, trends and determinants. In: Bolla M, van Poppel H (Hrsg) Management of prostate cancer. Springer, Cham Crocetti E (2015) Epidemiology of prostate cancer in Europe. Centre for Parliamentary Studies Statistik Austria (2018) Jahrbuch der Gesundheitsstatistik 2016 Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. Cancer J Clin 68(1):7–30 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): (2018) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0. AWMF Registernummer: 043/022OL. http://www.leitlinienprogrammonkologie.de/leitlinien/prostatakarzinom/. Zugegriffen: 9. Mai 2019 Janke K (2019) Prostatakarzinom. https://www.uro.at/patienten-informationen/patienten-ratgeber/55-prostatakarzinom.html. Zugegriffen: 13. Mai 2019 Patel AR, Klein EA (2009) Risk factors for prostate cancer. Nat Clin Pract Urol 6(2):87–95 Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P (2015) Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer 137(7):1749–1757 Dong C, Hemminki K (2001) Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer 92(1):144–150 Hemminki K, Czene K (2002) Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer 95(6):1346–1353 McWhorter WP, Hernandez AD, Meikle AW, Terreros DA, Smith JA Jr., Skolnick MH, Cannon-Albright LA, Eyre HJ (1992) A screening study of prostate cancer in high risk families. J Urol 148(3):826–828 Elshafei A, Moussa AS, Hatem A, Ethan V, Panumatrassamee K, Hernandez AV, Jones JS (2013) Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy? Urology 81(4):826–830 Zeegers MP, Jellema A, Ostrer H (2003) Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 97(8):1894–1903 Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89(8):3367–3371 Breast Cancer Linkage C (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91(15):1310–1316 Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS et al (2017) Prediction of breast and prostate cancer risks in Male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol 35(20):2240–2250 van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719 Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A et al (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72(1):1–12 Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O’Brien L, Sawyer E et al (2011) BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 105(8):1230–1234 Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O’Brien L et al (2012) Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 106(10):1697–1701 Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375(5):443–453 Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O’Leary E, Esplin ED, Nussbaum RL, Sartor O (2019) Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.6760 Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M et al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31(14):1748–1757 Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S et al (2008) Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98(2):502–507 Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE et al (2007) Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 99(12):929–935 Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V et al (2010) Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 16(7):2115–2121 Kathleen Cunningham Consortium for Research in Familial Breast Cancer C, Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, Mitchell G, Fox S, Hopper JL et al (2011) Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res 4(7):1002–1010 Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P et al (2010) Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 103(6):918–924 Bratt O, Loman N (2015) Clinical management of prostate cancer in men with BRCA mutations. Eur Urol 68(2):194–195 Pomerantz MM, Spisak S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O’Connor EP, Herbert ZT et al (2017) The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 123(18):3532–3539 Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33(3):244–250 Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373(18):1697–1708 Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, Govindasami K, Guy M, Ellis S, Frost D et al (2015) Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 68(2):186–193 Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K et al (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66(3):489–499 Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228 Daly MB, Pilarski R, Berry M, Buys SS, Friedman S, Garber JE, Klein C, Kohlmann W, Kurian A, Laronga C et al (2018) NCCN clinical practice guidelines in oncology. Genetic/familial high-risk assessement: breast and ovarian 2.2019. National comprehensive cancer network (NCCN) Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y et al (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366(2):141–149 Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK, Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D et al (2003) Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate 57(4):326–334 Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J et al (2005) A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 77(2):219–229 Zuhlke KA, Madeoy JJ, Beebe-Dimmer J, White KA, Griffin A, Lange EM, Gruber SB, Ostrander EA, Cooney KA (2004) Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. Clin Cancer Res 10(18 Pt 1):5975–5980 Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, Laasanen SL, Kallioniemi A, Nevanlinna H, Aaltonen L et al (2013) HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 22(3):452–460 Beebe-Dimmer JL, Hathcock M, Yee C, Okoth LA, Ewing CM, Isaacs WB, Cooney KA, Thibodeau SN (2015) The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies. Cancer Epidemiol Biomarkers Prev 24(9):1366–1372 Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, Wang X, Qi J, Chen Z, Zhou F et al (2013) A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 73(2):169–175 Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, Gronberg H, Wiklund F (2014) A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol 65(1):169–176 Chen Z, Greenwood C, Isaacs WB, Foulkes WD, Sun J, Zheng SL, Condreay LD, Xu J (2013) The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis 34(6):1260–1264 Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, Jones M, Jugurnauth-Little S, Govindasami K, Guy M et al (2015) Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol 26(4):756–761 MacInnis RJ, Severi G, Baglietto L, Dowty JG, Jenkins MA, Southey MC, Hopper JL, Giles GG (2013) Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E. PLoS ONE 8(2):e54727 Storebjerg TM, Hoyer S, Kirkegaard P, Bro F, LuCamp Study G, Orntoft TF, Borre M, Sorensen KD (2016) Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. BJU Int 118(4):646–653 Beebe-Dimmer JL, Isaacs WB, Zuhlke KA, Yee C, Walsh PC, Isaacs SD, Johnson AM, Ewing CE, Humphreys EB, Chowdhury WH et al (2014) Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. BJU Int 113(5):830–835 Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I, Fenwick K, Assiotis I, Barrowdale D et al (2014) Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer 110(6):1663–1672 Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J et al (2017) Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 71(5):740–747